Cargando…
Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk
BACKGROUND: The role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756457/ https://www.ncbi.nlm.nih.gov/pubmed/36526967 http://dx.doi.org/10.1186/s12874-022-01798-0 |
_version_ | 1784851633887248384 |
---|---|
author | Mehta, Tanvi Malinovsky, Yaakov Abnet, Christian C. Albert, Paul S. |
author_facet | Mehta, Tanvi Malinovsky, Yaakov Abnet, Christian C. Albert, Paul S. |
author_sort | Mehta, Tanvi |
collection | PubMed |
description | BACKGROUND: The role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibitively expensive. We propose a two-phase group testing design to more efficiently screen numerous antibody effects in a case-control setting. METHODS: Phase 1 uses group testing to select antibodies that are differentially expressed between cases and controls. The selected antibodies go on to Phase 2 individual testing. RESULTS: We evaluate the two-phase group testing design through simulations and example data and find that it substantially reduces the number of assays required relative to standard case-control and group testing designs, while maintaining similar statistical properties. CONCLUSION: The proposed two-phase group testing design can dramatically reduce the number of assays required, while providing comparable results to a case-control design. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01798-0. |
format | Online Article Text |
id | pubmed-9756457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97564572022-12-17 Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk Mehta, Tanvi Malinovsky, Yaakov Abnet, Christian C. Albert, Paul S. BMC Med Res Methodol Research BACKGROUND: The role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibitively expensive. We propose a two-phase group testing design to more efficiently screen numerous antibody effects in a case-control setting. METHODS: Phase 1 uses group testing to select antibodies that are differentially expressed between cases and controls. The selected antibodies go on to Phase 2 individual testing. RESULTS: We evaluate the two-phase group testing design through simulations and example data and find that it substantially reduces the number of assays required relative to standard case-control and group testing designs, while maintaining similar statistical properties. CONCLUSION: The proposed two-phase group testing design can dramatically reduce the number of assays required, while providing comparable results to a case-control design. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01798-0. BioMed Central 2022-12-16 /pmc/articles/PMC9756457/ /pubmed/36526967 http://dx.doi.org/10.1186/s12874-022-01798-0 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mehta, Tanvi Malinovsky, Yaakov Abnet, Christian C. Albert, Paul S. Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title | Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title_full | Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title_fullStr | Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title_full_unstemmed | Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title_short | Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
title_sort | using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756457/ https://www.ncbi.nlm.nih.gov/pubmed/36526967 http://dx.doi.org/10.1186/s12874-022-01798-0 |
work_keys_str_mv | AT mehtatanvi usinggrouptestinginatwophaseepidemiologicdesigntoidentifytheeffectsofalargenumberofantibodyreactionsondiseaserisk AT malinovskyyaakov usinggrouptestinginatwophaseepidemiologicdesigntoidentifytheeffectsofalargenumberofantibodyreactionsondiseaserisk AT abnetchristianc usinggrouptestinginatwophaseepidemiologicdesigntoidentifytheeffectsofalargenumberofantibodyreactionsondiseaserisk AT albertpauls usinggrouptestinginatwophaseepidemiologicdesigntoidentifytheeffectsofalargenumberofantibodyreactionsondiseaserisk |